Free Trial

Estrella Immunopharma (ESLA) Competitors

$1.16 +0.06 (+5.45%)
(As of 12/20/2024 05:16 PM ET)

ESLA vs. KYTX, MDWD, SGMT, HURA, CRBP, CRBU, DRUG, STRO, ACTU, and TSVT

Should you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Kyverna Therapeutics (KYTX), MediWound (MDWD), Sagimet Biosciences (SGMT), TuHURA Biosciences (HURA), Corbus Pharmaceuticals (CRBP), Caribou Biosciences (CRBU), Bright Minds Biosciences (DRUG), Sutro Biopharma (STRO), Actuate Therapeutics (ACTU), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical products" industry.

Estrella Immunopharma vs.

Kyverna Therapeutics (NASDAQ:KYTX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Kyverna Therapeutics' return on equity of -51.12% beat Estrella Immunopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Kyverna TherapeuticsN/A -51.12% -37.91%
Estrella Immunopharma N/A -195.77%-157.28%

In the previous week, Kyverna Therapeutics had 38 more articles in the media than Estrella Immunopharma. MarketBeat recorded 38 mentions for Kyverna Therapeutics and 0 mentions for Estrella Immunopharma. Kyverna Therapeutics' average media sentiment score of 0.09 beat Estrella Immunopharma's score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Kyverna Therapeutics Neutral
Estrella Immunopharma Neutral

Estrella Immunopharma has lower revenue, but higher earnings than Kyverna Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kyverna Therapeutics$7.03M24.56-$60.37MN/AN/A
Estrella ImmunopharmaN/AN/A-$7.31M-$0.26-4.46

Kyverna Therapeutics received 10 more outperform votes than Estrella Immunopharma when rated by MarketBeat users.

CompanyUnderperformOutperform
Kyverna TherapeuticsOutperform Votes
10
66.67%
Underperform Votes
5
33.33%
Estrella ImmunopharmaN/AN/A

Kyverna Therapeutics presently has a consensus price target of $25.71, indicating a potential upside of 542.86%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Estrella Immunopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyverna Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00
Estrella Immunopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Kyverna Therapeutics beats Estrella Immunopharma on 11 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESLA vs. The Competition

MetricEstrella ImmunopharmaBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$39.80M$2.94B$5.13B$9.08B
Dividend YieldN/A1.90%4.91%4.22%
P/E Ratio-4.4646.7391.4117.18
Price / SalesN/A411.851,113.72116.79
Price / CashN/A182.1042.7137.86
Price / Book9.673.894.794.78
Net Income-$7.31M-$42.21M$120.07M$225.60M
7 Day Performance-2.82%-2.15%-1.92%-1.23%
1 Month Performance28.18%4.20%11.46%3.36%
1 Year Performance-6.45%18.39%30.49%16.59%

Estrella Immunopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ESLA
Estrella Immunopharma
0.1528 of 5 stars
$1.16
+5.5%
N/A-7.2%$39.80MN/A-4.46N/AGap Down
KYTX
Kyverna Therapeutics
2.4277 of 5 stars
$4.24
-4.1%
$25.71
+506.5%
N/A$183.05M$7.03M0.0096News Coverage
MDWD
MediWound
1.9097 of 5 stars
$16.75
-3.1%
$27.50
+64.2%
+58.3%$180.67M$19.72M-5.9380Positive News
Gap Down
SGMT
Sagimet Biosciences
2.3293 of 5 stars
$5.73
+30.5%
$23.00
+301.4%
-8.0%$175.74M$2M0.008Gap Up
High Trading Volume
HURA
TuHURA Biosciences
N/A$4.14
-16.0%
$15.00
+262.3%
N/A$175.06MN/A0.00N/AAnalyst Forecast
News Coverage
CRBP
Corbus Pharmaceuticals
3.9067 of 5 stars
$14.28
-5.3%
$62.00
+334.2%
+147.6%$173.93M$880,000.00-3.2240
CRBU
Caribou Biosciences
2.2028 of 5 stars
$1.91
flat
$10.20
+434.0%
-69.4%$172.96M$11.48M-1.16100
DRUG
Bright Minds Biosciences
3.5828 of 5 stars
$38.82
-5.3%
$75.00
+93.2%
+2,621.8%$172.13MN/A-60.29N/ANews Coverage
Gap Up
STRO
Sutro Biopharma
4.4663 of 5 stars
$2.07
-2.4%
$11.13
+437.4%
-51.3%$170.69M$153.73M-1.29240High Trading Volume
ACTU
Actuate Therapeutics
N/A$8.69
+0.8%
N/AN/A$169.73MN/A0.0010Gap Up
TSVT
2seventy bio
2.2166 of 5 stars
$3.26
-0.3%
$9.00
+176.1%
-7.1%$168.18M$100.39M-1.76440Positive News

Related Companies and Tools


This page (NASDAQ:ESLA) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners